• search hit 2 of 6
Back to Result List

Psychiatric comorbidities in 1p36 deletion syndrome and their treatment — a case report

Please always quote using this URN: urn:nbn:de:bvb:20-opus-250189
  • 1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap,1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Wolfgang Briegel
URN:urn:nbn:de:bvb:20-opus-250189
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie
Language:English
Parent Title (English):International Journal of Environmental Research and Public Health
ISSN:1660-4601
Year of Completion:2021
Volume:18
Issue:22
Article Number:12064
Source:International Journal of Environmental Research and Public Health (2021) 18:22, 12064. https://doi.org/10.3390/ijerph182212064
DOI:https://doi.org/10.3390/ijerph182212064
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:1p36 deletion syndrome; attention deficit/hyperactivity disorder; case report; melatonin; methylphenidate; off label use; oppositional-defiant disorder; parent-child interaction therapy (PCIT)
Release Date:2022/10/07
Date of first Publication:2021/11/17
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International